Hims & Hers Health Hits Analyst Target, What’s Next?

Hims & Hers Health recently surpassed the average analyst target price, prompting investors to evaluate future expectations. Analysts maintain diverse views on the stock, with a mix of buy and sell ratings contributing to an overall assessment of $2.57.

Date: 03-03-2025

AI Rating: 6

Stock Surpasses Analyst Target
Hims & Hers Health Inc (Symbol: HIMS) has recently crossed above the average analyst 12-month target price of $43.57, currently trading at $45.09/share. This signals a potential reassessment by analysts.

Investors should consider the mixed analyst targets for HIMS—with predictions ranging widely from $16.00 to $85.00—indicating differing expectations about the company's future performance. This divergence in opinions reflects uncertainty in valuation and the ability of the company to sustain growth beyond current expectations.

Analyst Ratings Breakdown
The report shows a breakdown of analyst ratings, with 4 strong buy ratings, 1 buy rating, 7 hold ratings, 1 sell rating, and 1 strong sell rating. The average rating is 2.57, suggesting a cautious outlook amidst the varying opinions from analysts. The trend shows that while strong buy ratings have remained stable, there has been an increase in hold ratings over the past months, suggesting a more conservative approach among analysts.

As HIMS has met the average target, investors may be prompted to re-evaluate their positions: whether to hold for potential further gains or sell to capitalize on current price movements. The wide spread in price targets indicates that many investors will need to analyze the underlying fundamentals further to draw informed conclusions about future performance, potentially affecting stock prices as analysts update their views.

Stocks: HIMS